{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-033618","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2022-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.820609+00:00","generated_at":"2026-06-26T22:50:10.936676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Entrada Therapeutics reports FY2021 net loss of $51.2M; cash at $291.1M","bullets":["Net loss of $18.4M in Q4'21 and $51.2M for FY2021, vs $8.7M and $26.5M in 2020.","Cash and equivalents $291.1M as of Dec 31, 2021, including $190.7M net from Nov 2021 IPO.","R&D expenses $12.4M in Q4 ($35.9M FY), up from $6.7M ($21.1M) YoY on preclinical studies.","On track to submit IND for ENTR-601-44 (DMD exon 44) in 2H 2022.","Appointed Jared Cohen, PhD, JD as General Counsel in January 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-033618","json":"https://secwatch.observer/filing/0001104659-22-033618.json","markdown":"https://secwatch.observer/filing/0001104659-22-033618.md","text":"https://secwatch.observer/filing/0001104659-22-033618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922033618/0001104659-22-033618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922033618/tm228415d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:50:10.936676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}